RETRACTED: Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Dossier post-publication
OpenAlex signale ce travail comme rétracté, mais aucune notice correspondante de Retraction Watch ne figure dans cette base.
Résumé
Prostate cancer is among most malignant tumors around the world and this urological tumor can be developed as result of genomic mutations and their accumulation during progression towards advanced stage. Due to lack of specific symptoms in early stages of prostate cancer, most cancer patients are diagnosed in advanced stages that tumor cells display low response to chemotherapy. Furthermore, genomic mutations in prostate cancer enhance the aggressiveness of tumor cells. Docetaxel and paclitaxel are suggested as well-known compounds for chemotherapy of prostate tumor and they possess a similar function in cancer therapy that is based on inhibiting depolymerization of microtubules, impairing balance of microtubules and subsequent delay in cell cycle progression. The aim of current review is to highlight mechanisms of paclitaxel and docetaxel resistance in prostate cancer. When oncogenic factors such as CD133 display upregulation and PTEN as tumor-suppressor shows decrease in expression, malignancy of prostate tumor cells enhances and they can induce drug resistance. Furthermore, phytochemicals as anti-tumor compounds have been utilized in suppressing chemoresistance in prostate cancer. Naringenin and lovastatin are among the anti-tumor compounds that have been used for impairing progression of prostate tumor and enhancing drug sensitivity. Moreover, nanostructures such as polymeric micelles and nanobubbles have been utilized in delivery of anti-tumor compounds and decreasing risk of chemoresistance development. These subjects are highlighted in current review to provide new insight for reversing drug resistance in prostate cancer.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
La notice
- Revue
- Biomedicine & Pharmacotherapy
- Thématique
- Prostate Cancer Treatment and Research
- Domaine
- Medicine
- Établissements canadiens
- University of British Columbia
- Organismes subventionnaires
- —
- Mots-clés
- Prostate cancerDocetaxelMedicinePaclitaxelCancer researchCancerProstateCabazitaxelPTENTumor progressionOncologyMalignancyInternal medicineAndrogen deprivation therapyBiologyPI3K/AKT/mTOR pathwayApoptosis
- Résumé présent dans OpenAlex
- oui